1. Home
  2. SCLX vs SDST Comparison

SCLX vs SDST Comparison

Compare SCLX & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • SDST
  • Stock Information
  • Founded
  • SCLX 2011
  • SDST 2022
  • Country
  • SCLX United States
  • SDST United States
  • Employees
  • SCLX N/A
  • SDST N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • SDST Blank Checks
  • Sector
  • SCLX Health Care
  • SDST Finance
  • Exchange
  • SCLX Nasdaq
  • SDST Nasdaq
  • Market Cap
  • SCLX 35.7M
  • SDST 34.3M
  • IPO Year
  • SCLX N/A
  • SDST N/A
  • Fundamental
  • Price
  • SCLX $18.87
  • SDST $0.40
  • Analyst Decision
  • SCLX Strong Buy
  • SDST Buy
  • Analyst Count
  • SCLX 3
  • SDST 2
  • Target Price
  • SCLX $367.50
  • SDST $1.70
  • AVG Volume (30 Days)
  • SCLX 324.6K
  • SDST 1.4M
  • Earning Date
  • SCLX 08-13-2025
  • SDST 08-13-2025
  • Dividend Yield
  • SCLX N/A
  • SDST N/A
  • EPS Growth
  • SCLX N/A
  • SDST N/A
  • EPS
  • SCLX N/A
  • SDST N/A
  • Revenue
  • SCLX $44,236,000.00
  • SDST N/A
  • Revenue This Year
  • SCLX $89.26
  • SDST N/A
  • Revenue Next Year
  • SCLX $203.95
  • SDST $246.67
  • P/E Ratio
  • SCLX N/A
  • SDST N/A
  • Revenue Growth
  • SCLX N/A
  • SDST N/A
  • 52 Week Low
  • SCLX $3.60
  • SDST $0.14
  • 52 Week High
  • SCLX $45.15
  • SDST $12.56
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 63.34
  • SDST 49.55
  • Support Level
  • SCLX $15.61
  • SDST $0.38
  • Resistance Level
  • SCLX $22.01
  • SDST $0.46
  • Average True Range (ATR)
  • SCLX 2.21
  • SDST 0.03
  • MACD
  • SCLX -0.14
  • SDST -0.00
  • Stochastic Oscillator
  • SCLX 62.35
  • SDST 39.90

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About SDST Stardust Power Inc. Common Stock

Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).

Share on Social Networks: